866-997-4948(US-Canada Toll Free)

Ovarian cancer is a growth of abnormal malignant cells that originates in the ovaries (women’s reproductive glands that produce ova) and spreads to other parts of the body. Ovarian cancer can occur at any age; however it commonly occurs in women aged over 50 years. 

While the causes of ovarian cancer are still unknown, researchers have their own theories to condition. Some of the risk factors causing ovarian cancer are associated genetic syndromes and increased hormone levels before and during ovulation that stimulates the growth of abnormal cells. Most of the ovarian cancers are either a type of ovarian epithelial carcinomas (cancer that begins in the cells on the surface of the ovary) or they are malignant germ cell tumors (cancer that begins in egg cells). 

According to the global statistics, ovarian cancer accounts for 5% of all types of cancers among women causing severe deaths as compared to other female genital tract cancer. Earlier, the market for ovarian cancer was valued at $16 billion in 2012, which is further expected to grow and reach a value of $34.6 billion in 2018. This is estimated to increase at a five-year compound annual growth rate (CAGR) of 13.1%. 

The market focuses on the diagnostics and therapeutic development for overcoming ovarian cancer. Within the vast and competitive landscape of ovarian cancer therapies, the market has introduced surgery, trans-vaginal ultrasound, blood test, imaging test, chemotherapy, and other novel therapy methods for the treatment of this cancer.  

ResearchMoz offers an introspective outlook on the overall market trend of ovarian cancer. We regularly update our comprehensive collection of market research reports from leading international publishers in matters related to ovarian cancer and more. For more information contact a Research Associate at ResearchMoz today.